title: Safety and feasibility of S-1 adjuvant chemotherapy for pancreatic cancer in elderly patients.
abstract: BACKGROUND
  The safety and feasibility of administering S-1 adjuvant chemotherapy for pancreatic cancer has not yet been fully evaluated in elderly patients.
  
  
  METHODS
  This retrospective study selected patients who underwent curative surgery for pancreatic cancer, were diagnosed with stage II disease or lower or stage III disease with combined resection of the celiac artery, and received adjuvant S-1 at our institution. The patients were categorized into two groups: non-elderly patients (<70 years of age: group A) and elderly patients (>70 years of age: group B). The toxicity and S-1 continuation rates were compared between the two groups.
  
  
  RESULTS
  A total of 76 patients were evaluated in the present study. There were no grade 4 toxicities. The incidences of grade 3 hematological and non-hematological toxicities were <5 % in both groups, and the differences were not significantly different. The continuation rate at 6 months was 60.5 % in group A and 72.7 % in group B, which was also not significantly different.
  
  
  CONCLUSIONS
  These results suggest that S-1 adjuvant chemotherapy for pancreatic cancer is safe and feasible, regardless of the age of the patient, especially for elderly patients who may be candidates for clinical trials.
authors.affiliation: Department of Gastrointestinal Surgery, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, Yokohama, 241-8515, Japan, aoyamat@kcch.jp.
authors.forename: Toru
authors.initials: T
authors.lastname: Aoyama
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Katayama
authors.forename: Masaaki
authors.initials: M
authors.lastname: Murakawa
authors.forename: Yosuke
authors.initials: Y
authors.lastname: Atsumi
authors.forename: Koichiro
authors.initials: K
authors.lastname: Yamaoku
authors.forename: Amane
authors.initials: A
authors.lastname: Kanazawa
authors.forename: Akio
authors.initials: A
authors.lastname: Higuchi
authors.forename: Manabu
authors.initials: M
authors.lastname: Shiozawa
authors.forename: Satoshi
authors.initials: S
authors.lastname: Kobayashi
authors.forename: Makoto
authors.initials: M
authors.lastname: Ueno
authors.forename: Manabu
authors.initials: M
authors.lastname: Morimoto
authors.forename: Naoto
authors.initials: N
authors.lastname: Yamamoto
authors.forename: Takashi
authors.initials: T
authors.lastname: Oshima
authors.forename: Takaki
authors.initials: T
authors.lastname: Yoshikawa
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Rino
authors.forename: Munetaka
authors.initials: M
authors.lastname: Masuda
authors.forename: Soichiro
authors.initials: S
authors.lastname: Morinaga
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage* / Q000009:adverse effects*; D017024:Chemotherapy, Adjuvant / Q000009:adverse effects*; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging / Q000379:methods; D010094:Oxonic Acid / Q000008:administration & dosage* / Q000009:adverse effects*; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D012189:Retrospective Studies; D005641:Tegafur / Q000008:administration & dosage* / Q000009:adverse effects*
chemical_list: D000964:Antimetabolites, Antineoplastic; D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid